Seres Therapeutics Q3 2023 $(0.37) Beats $(0.50) Estimate
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics reported Q3 2023 earnings, with a loss of $0.37 per share, beating the estimate of a $0.50 loss per share.
November 02, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics, trading as MCRB, reported better than expected Q3 2023 earnings, which could positively impact the stock price in the short term.
Earnings reports are a significant factor in a company's stock price. In this case, Seres Therapeutics reported a smaller loss than expected, which is generally seen as positive news by investors and could lead to an increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100